form_8-k.htm
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________
Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):
March 5, 2010

SCOLR Pharma, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
  
001-31982
  
91-1689591
(State or other jurisdiction of incorporation)
  
(Commission File No.)
  
(I.R.S. Employer Identification No.)

19204 North Creek Parkway, Suite 100
Bothell, WA 98011
(Address of principal executive offices)

(425) 368-1050
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
1
 
Item 7.01.  Regulation FD Disclosure.
 
SCOLR Pharma, Inc., a Delaware corporation (the “Company”), has been informed by Chrono Nutraceuticals LLC, a newly formed Arizona limited liability company (“Chrono”), that Chrono is currently unable to perform the terms of its License Agreement with the Company dated as of November 20, 2009 (the “Agreeement”) due to financial problems.  Under the terms of the Agreement, Chrono paid SCOLR an initial fee of $25,000 and agreed to pay an additional $87,500 that became due on January 31, 2010.  Chrono has failed to deliver this additional payment.  The Company is considering its available remedies with respect to the Agreement.  


 
2
 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
SCOLR PHARMA, INC.
Dated:  March 5, 2010
By:
/s/ Richard M. Levy
   
Chief Financial Officer
 

3